...
首页> 外文期刊>Travel medicine and infectious disease >Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A?meta-analysis and systematic review
【24h】

Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A?meta-analysis and systematic review

机译:预防血管血管疟原虫和疟原虫疟原虫在旅行者中的预防疗效:a?荟萃分析和系统审查

获取原文
获取原文并翻译 | 示例

摘要

Abstract Background With increased international travel over the world the need for safe and effective chemoprophylaxis for malaria is as great as ever. The choice of regimen is difficult, as effectiveness should be weighted against potential adverse effects. Although, some studies have reported high prophylactic efficacy of primaquine, there is no comprehensive evidence comparing its prophylactic effectiveness as well as toxicity. To fill the gap, this systematic review and meta-analysis study was carried out. Methods Using MeSH terms, 756 records were detected through searching “Pubmed”, “Embase”,”Web of Science”and “Cochrane” databases. From these,7 relevant full-text articles with 14 comparisons for final quantitative meta-analysis were included in our review. In order to make a comparison between the studies, Risk Ratios(RRs) and their 95% confidence intervals(CIs) were estimated. Results Overall,74% reduction in the incidence of parasitaemia by primaquine versus other prophylactic regimens was estimated(RRoverall?=?0.26, CI 95%:0.16–0.41--RRvivax?=?0.16, CI 95%:0.07–0.36--RRfalciparum?=?0.31, CI 95%:0.18–0.55). The incidence rate ratios for adverse effects showed no statistically significant difference between primaquine and control groups (p??0.05). Conclusions For persons without G6PD deficiency, who are not pregnant, primaquine is the most effective presently available prophylactic for P. vivax malaria and comparable to such regimens as doxycycline, mefloquine and atovaquone-proguanil for the prevention of P. falciparum malaria. ]]>
机译:摘要背景与世界上涨的增加,对疟疾的安全性和有效的化学介性的需求与以往一样伟大。方案的选择是困难的,因为有效性应加权免受潜在的不利影响。虽然,一些研究报告了初始预防疗效,但没有全面的证据,比较其预防性效果以及毒性。为了填补差距,进行了这种系统审查和荟萃分析研究。使用网格术语的方法,通过搜索“Pubmed”,“Embase”,“科学”和“Cochrane”数据库来检测756个记录。从这些中,7个相关的全文文章包含14条比较的最终定量Meta分析的比较,包括在我们的审核中。为了比较研究,估计风险比(RRS)及其95%置信区间(CIS)。结果总体而言,据估计了寄生虫与其他预防性方案的寄生虫的发生率降低了74%(RROVERALL?= 0.26,CI 95%:0.16-0.41 - RRVivax?=?0.16,CI 95%:0.07-0.36-- Rrfalciparum?= 0.31,CI 95%:0.18-0.55)。不良反应的发病率比没有在原序和对照组之间没有统计学显着差异(p?&Δ05)。结论对于没有妊娠的没有G6PD缺乏的人,原始是最有效的本预防性的P.Vivax疟疾,并与该等药物的那种治疗方案相当,用于预防P.Malciparum疟疾的P. falciparum疟疾。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号